Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer

Vargens, Daniela D.; Neves, Ronaldo R.S.; Bulzico, Daniel A.; Ojopi, Élida B.; Meirelles, Ricardo M.R.; Pessoa, Cencita N.; Prado, Carolina M.; Gonçalves, Pedro A.; Leal, Vera L.G.; Suarez-Kurtz, Guilherme

Pharmacogenetics and Genomics: June 2011 - Volume 21 - Issue 6 - p 341–343
doi: 10.1097/FPC.0b013e3283448d19

There is a considerable interindividual variation in L-thyroxine [3,5,3′,5′-tetraiodo-l-thyronine (T4)] dose required for thyrotropin (thyroid-stimulating hormone) suppression in patients with differentiated thyroid cancer. To investigate whether uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)-mediated T4 glucuronidation in liver affects T4 dose, we genotyped 101 patients for the common UGT1A1-53(TA)n polymorphism and compared T4 doses among patients having zero (5/6 and 6/6 genotypes), one (6/7 genotype), or two (7/7 and 7/8 genotypes) copies of the low-expression (TA)7 and (TA)8 alleles. A significant trend for decreasing T4 dose with increasing number of copies of (TA)7 and (TA)8 (P=0.037) and significant difference in T4 dose across the UGT1A1-53(TA)n genotypes (P=0.048) were observed, despite considerable overlap of T4 doses among different genotypes. These results are consistent with reduced T4 glucuronidation in patients with low-expression (TA)7 and (TA)8 alleles and provide the first evidence for association between UGT1A1-53(TA)n and T4-dose requirement for thyroid-stimulating hormone suppression in a natural clinical setting.

aDivisão de Farmacologia

bServiço de Endocrinologia, Instituto Nacional de Câncer

cServiço de Endocrinologia, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rio de Janeiro

dLaboratório de Neurociências (LIM-27), Instituto de Psiquiatria, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Correspondence to Guilherme Suarez-Kurtz, MD, PhD, Divisão de Farmacologia, Instituto Nacional de Câncer, RJ 20231-050, Rio de Janeiro, Brazil Tel: +55213207 6502; fax: +552132076542;e-mail:

Received November 26, 2010

Accepted January 12, 2011

Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.